AbbVie's Dual-Targeting Therapy Shows Higher Remission Rates In Mid-Stage Crohn's Disease Study
AbbVie's Phase 2a study of ABBV-466, a dual-targeting therapy for Crohn's disease, showed higher remission rates than its components alone. At Week 12, 30.2% of patients achieved remission, rising to 40.5% by Week 24. The study included 300 patients, many of whom had failed prior therapies. ABBV-466 combines risankizumab and trosunilimab. The stock closed at $285.42 on October 16, 2026, and was down 0.17% in pre-market trading.
How this was made
The 30-second read
Why it matters
The trial shows a 40.5% remission rate at week 24 versus ~20% for comparators, indicating a potentially differentiated product.
Market read
First‑time disclosure of Phase 2a efficacy data for a novel Crohn's therapy, likely to influence AbbVie's stock and sector sentiment.
What to watch
Potential safety concerns and competition from existing IL‑23 inhibitors could limit upside.
Background
AbbVie presented the data at the 2026 United European Gastroenterology Week congress, highlighting its dual‑targeting approach combining risankizumab and an investigational α4β7 inhibitor.
Ticker impact
AbbVie disclosed positive Phase 2a results for its investigational dual‑targeting therapy ABBV‑466 in Crohn's disease, showing higher remission rates than monotherapies.
likely upward pressure as investors price in potential future revenue from a novel Crohn's treatment.
Phase 2a data is material for a biotech pipeline; market typically reacts favorably to early‑stage efficacy signals.
Market effects
strengthens outlook for gastro‑intestinal biotech segment and may boost peer valuations.
U.S. biotech stocks could see modest gains in early trading.
Adds to global pipeline momentum for inflammatory disease therapies.
Counterpoint
Investors may remain cautious until Phase 3 data confirms durability and safety.
Key entities
- companyAbbVie
Pharmaceutical company developing ABBV‑466.
- drugSkyrizi
Commercial IL‑23 inhibitor component of ABBV‑466.